CRL Charles River Laboratories
Dominant preclinical toll booth; impairments hide about 19% margins, but non-animal methods cap the upside.
The story
Charles River is the preclinical toll booth: it holds dominant share in research models and outsourced safety assessment, and has decades of regulatory trust and scale that rivals cannot easily copy. The business is mature and cyclical. Revenue has been flat for three years because biotech funding and pricing softened, and GAAP margins collapsed to 0.2%, mainly from goodwill impairments and restructuring rather than lost economics. The long-term questions are whether the FDA push toward non-animal methods (NAMs) shrinks the core, and whether the company can adapt by adding those methods itself.
My previous value of $70.65 was about 77% below a heavily covered price, so I revisited the drivers. Target margin rises from 17% to 19%, close to the roughly 20% non-GAAP run-rate, because the 0.2% print is mostly non-cash impairments, intangible amortization is fading, and cost cuts are underway. Sales-to-capital rises from 1.0 to 1.4: the reported 0.75 is weighed down by acquired goodwill, while capex runs below D&A, so growth needs little new capital. Year-1 growth rises from 2.5% to 4% on the biotech funding recovery, and the horizon extends one year to 8 for the scale moat. My value probably still sits below the market, which already prices in a full recovery.
Value drivers
| Revenue growth (Y1) | 4.0% |
| Terminal growth | 3.0% |
| Forecast horizon | 8y |
| Target operating margin | 19.0% |
| Years to target margin | 3 |
| Sales-to-capital | 1.40 |
| Beta | 1.05 |
| Failure probability | 2.0% |
| Cost of capital (WACC) | 9.6% |
| Terminal WACC | 9.4% |
Valuation bridge
| PV of explicit FCFF | 2.59B |
| PV of terminal value | 4.14B |
| Equity value | 4.69B |
| ÷ shares → per share | $97.95 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 4.14B | 4.0% | 6.5% | 211.96M | 113.62M | 98.33M | 89.73M |
| 2 | 4.30B | 3.9% | 12.7% | 432.44M | 113.95M | 318.49M | 265.18M |
| 3 | 4.46B | 3.7% | 19.0% | 668.70M | 113.96M | 554.74M | 421.46M |
| 4 | 4.61B | 3.6% | 19.0% | 692.58M | 113.65M | 578.93M | 401.35M |
| 5 | 4.77B | 3.4% | 19.0% | 716.33M | 113.00M | 603.33M | 381.65M |
| 6 | 4.93B | 3.3% | 19.0% | 739.86M | 112.00M | 627.86M | 362.41M |
| 7 | 5.08B | 3.1% | 19.0% | 763.11M | 110.65M | 652.46M | 343.65M |
| 8 | 5.24B | 3.0% | 19.0% | 786.01M | 108.94M | 677.06M | 325.40M |
Key risks
- FDA and NIH push toward non-animal methods structurally shrinks safety-assessment and research-model volumes
- Biotech funding relapse, pricing pressure in Discovery & Safety Assessment, or pharma insourcing
- Supply-chain issues for non-human primates and further write-downs of acquired assets, with net debt at $1.9B
Catalysts
- Safety-assessment book-to-bill above 1.0 with stable pricing as biotech funding recovers
- Margin recovery to 19-20% from restructuring, with impairment charges dropping out of GAAP results